Clinically, trastuzumab is approved for the treatment of HER2-positive breast cancer, including early-stage disease, where it is often used in adjuvant or neoadjuvant settings to reduce recurrence risk, and metastatic BC, typically in combination with chemotherapy [96] or other HER2-targeted therapies [97]. The gene discussed is ERBB2; the disease is breast cancer.